<![CDATA[Novo Nordisk A/S - Stock Exchange Announcements]]><![CDATA[Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B]]>Bagsværd, Denmark, 17 May 2013 - Novo Nordisk today announced the completion of paradigm(TM) 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm(TM) 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.

Further information

Company announcement No 37 (...)

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 13 May 2013 - On 3 May 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.

Further information

Company announce (...)

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 3 May 2013 - As part of the execution of Novo Nordisk A/S' on-going share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013, a new share repurchase programme has been initiated in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announceme (...)

]]><![CDATA[Novo Nordisk A/S purchases B shares worth DKK 2.5 billion from Novo A/S as part of the on-going share repurchase programme]]>Bagsværd, Denmark, 3 May 2013 - Novo Nordisk A/S has today entered into an agreement to purchase 2,550,000 B shares (nominal DKK 1) of a value of DKK 2.5 billion from Novo A/S. This transaction is part of the on-going share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013. The transaction price is set to DKK 981.84 per share and has been calculated as the average market price from 1 May 2013 to 3 May 2013 in the open trading win (...)

]]><![CDATA[Trading in Novo Nordisk shares by board members, executives and associated persons on 1 May 2013]]>Bagsvaerd, Denmark, 2 May 2013 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Further information

Company announcement No 33 / 2013 

 

]]><![CDATA[Increased operating profit by 18% in the first quarter of 2013]]>Sales increased by 14% in local currencies and by 13% to 20.0 billion in Danish kroner.

  • Sales of modern insulins increased by 16% (14% in Danish kroner).
  • Sales of Victoza® increased by 36% (35% in Danish kroner).
  • Sales in North America increased by 24% (23% in Danish kroner).
  • Sales in International Operations increased by 17% (13% in Danish kroner).

Gross margin improved by 1.1 percentage points in Danish kroner to 81.9%, reflect (...)

]]><![CDATA[Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013]]>Bagsværd, Denmark, 30 April 2013 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. 

Further information

Company announcement No 31 / 2013

 

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 30 April 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

 

Further information:

Company Announcement 30 / 2013

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 22 April 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announcement No 29 / 2013

]]><![CDATA[Reduction of the share capital]]>Bagsværd, Denmark, 22 April 2013 - At Novo Nordisk's Annual General Meeting on 20 March 2013, it was decided to reduce the company's B share capital from DKK 452,512,800 to DKK 442,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 10,000,000 B shares of DKK 1 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10 (...)

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 15 April 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

  Further information

 

Company announcement No 27 / 2013

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 8 April 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announcement No 26 / 2013

]]><![CDATA[Status regarding Novo Nordisk's holding of its own shares (31 March 2013)]]>Bagsværd, Denmark, 2 April 2013 - In continuation of the company's announcements dated 9 November 2013 and 31 January 2013 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2013 owned 19,658,329 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 19,658,329 or 3.5% of the total share capital. (...)

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>Bagsværd, Denmark, 2 April 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announcement No 24 / 2013

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 25 March 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announcement No 23 No / 2013

]]><![CDATA[2013 long-term, share based incentive programme for the Senior Management Board]]>Bagsværd, Denmark, 21 March 2013 - The long-term, share-based incentive programme for 2013 for the Senior Management Board has been approved by the Board of Directors.

Further information

Company announcement No 22 / 2013

]]><![CDATA[Resolutions from the Annual General Meeting of Novo Nordisk A/S]]>Bagsværd, Denmark, 20 March 2013 - Today, 20 March 2013, Novo Nordisk A/S held the Annual General Meeting at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 Copenhagen V, Denmark. At the General Meeting, the shareholders adopted the following...

Further information

Company announcement No 21 / 2013

]]><![CDATA[Share repurchase programme]]>Bagsværd, Denmark, 18 March 2013 - On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company announcement No 20 / 2013

]]><![CDATA[People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial]]>Bagsværd, Denmark, 18 March 2013 - Novo Nordisk today announced the headline results from a 56-week, double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in overweight or obese people with type 2 diabetes. This is the second phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment.

Further information

Company  (...)

]]><![CDATA[Novo Nordisk A/S : share repurchase programme]]>Bagsværd, Denmark, 11 March 2013 - On 31 January 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information

Company Announcement No 18 / 2013

 

 

 

 

]]>